Mixed responses to first‐line alectinib in non‐small cell lung cancer patients with rare ALK gene fusions: A case series and literature review

Journal of Cellular and Molecular Medicine

Songan Chen¹  Yina Wang²  Mengnan Li²  Qiusu Tang³  Zhou An⁴  Junrong Yan⁵  Yutong Ma⁵ 

[1] Burning Rock Biotech, Guangzhou, China;Department of Medical Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China;Department of Pathology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China;Department of Thoracic Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China;Nanjing Geneseeq Technology Inc., Nanjing, China;

关键词: alectinib;    LMO7‐ALK;    NSCLC;    ALK;    STRN‐ALK;    survival;   

DOI  :  10.1111/jcmm.16897

来源: Wiley

【 授权许可】

CC BY